Latest Insights - page 63 | BiopharmaTrend

Lantern Pharma Advances Development of Molecular Diagnostic for Oncology Clinical Trials

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company, has reached a milestone in the development of a diagnostic tool for its drug candidate LP-184. This diagnostic, which utilizes quantitative real-time …

Continue ›››

Concr Launches VISION Trial Using Digital Twins for Predicting Breast Cancer Outcomes

Concr has initiated the recruitment of patients for the VISION trial, an observational clinical study designed to evaluate Concr's predictive algorithm that utilizes biomarkers to determine chemotherapy and immunotherapy responses …

Continue ›››

Advances in LBP Manufacturing: Microbiotica and Biose Industrie Prepare for Clinical Studies

Microbiotica, a biotechnology firm focused on developing precision microbiome medicines known as live biotherapeutic products (LBPs), is preparing for clinical trials targeting advanced melanoma and ulcerative colitis. The company will …

Continue ›››

Biostate AI Launches RNA Sequencing and Data Analysis Services

Biostate AI, a startup focused on scalable biodata solutions, has launched two new service products aimed at advancing multiomic data collection and AI training. The company introduced its Total RNA …

Continue ›››

Light-weight Microscope Captures Large-scale Brain Activity in Freely Moving Mice

Researchers at Rockefeller University have developed a new lightweight microscope capable of capturing large-scale brain activity in mice while they move freely. Published in Nature Biomedical Engineering, the study presents …

Continue ›››

Myricx Bio Secures £90m Series A Funding to Progress NMTi-ADC Therapeutics into Clinical Trials

Myricx Bio, a UK-based biotechnology company specializing in novel antibody-drug conjugates (ADCs), has raised £90 million ($114 million) in a Series A financing round. The funding was co-led by Novo …

Continue ›››

FDA Approves Signet Therapeutics' IND Application for sigx1094 in Diffuse Gastric Cancer

Signet Therapeutics, a biotechnology company specializing in targeted cancer therapy, has received FDA approval for its Investigational New Drug (IND) application for sigx1094. This drug candidate is aimed at treating …

Continue ›››

OMNY Health Partners with QuantHealth and ArisGlobal to Enhance AI-Driven Healthcare Solutions

OMNY Health, a healthcare ecosystem specializing in compliant cross-industry data sharing, has launched a platform designed to support AI-driven health technology companies. This platform facilitates the use of large de-identified …

Continue ›››

Aptamer Group Partners with AstraZeneca to Explore Optimer Vehicles for siRNA Delivery

Aptamer Group, a developer of novel Optimer® binders for the life sciences industry, has entered into an agreement with AstraZeneca to evaluate the use of Optimer fibrotic liver delivery vehicles …

Continue ›››

Waypoint Bio Secures $14.5 Million to Advance Drug Discovery with Innovative In Vivo Spatial Pooled Screening Technology

Waypoint Bio, a biotechnology company focused on developing novel cell therapies for solid tumors, has raised $14.5 million in seed funding. This funding round, led by Hummingbird Ventures with contributions …

Continue ›››

A Booming Anti-Obesity Drug Discovery Landscape at a Glance (With Challenges)

In 1986, Danish scientist Jens Juul Holst discovered that the gut hormone GLP-1 stimulates insulin and suppresses appetite. This research led to the development of two blockbuster weight-loss drugs: Wegovy …

Continue ›››

New DNA-Editing Technique Offers Potential for Advanced Genome Engineering

Researchers at the Arc Institute in California have identified a novel DNA-editing mechanism in bacteria, dubbed the “bridge editing” system, which promises to enable larger and more precise genomic modifications …

Continue ›››